Efficacy and Safety of Subcutaneous Anifrolumab in Adults with Moderate-to-Severe Systemic Lupus Erythematosus: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

The primary objective of this study is to compare the **efficacy** of anifrolumab with placebo on overall disease activity in patients with moderate-to-severe **Systemic Lupus Erythematosus (SLE)**. This is clinically relevant as SLE is a chronic autoimmune disease characterized by periods of increased disease activity, and effective management of overall disease activity is crucial for improving patient outcomes.

Secondary objectives include:

• Comparing the efficacy of anifrolumab with placebo on improvement in overall disease activity and low (or reduced) oral corticosteroid (OCS) use.
• Comparing the efficacy of anifrolumab with placebo on the onset of a sustained reduction in disease activity.
• Comparing the efficacy of anifrolumab with placebo on the onset of the first flare.

The clinical trial involves a total of **280 participants** diagnosed with **moderate-to-severe Systemic Lupus Erythematosus (SLE)**. The study population includes both male and female subjects, with an age range that encompasses both pediatric and adult patients. Participants were selected based on specific inclusion criteria, such as a confirmed diagnosis of SLE according to the ACR 1997 revised criteria for at least 24 weeks prior to enrollment. The trial includes individuals who are on stable background therapy with antimalarials, immunosuppressants, and glucocorticoids, either alone or in combination. Lifestyle considerations include the requirement for females of childbearing potential to use effective contraception methods and for males to use condoms during the study and for a specified period after the final dose. The trial also involves a vulnerable population, indicating additional ethical considerations in the study design. Participants must have a total SLEDAI-2K score of 6 or more, with at least 4 points from clinical components, and meet specific disease activity criteria as confirmed by the Disease Activity Central Review Team.

The clinical trial is a **randomized**, **double-blind**, **placebo-controlled** Phase 3 study designed to evaluate the efficacy and safety of subcutaneous **anifrolumab** in adult patients with moderate-to-severe **Systemic Lupus Erythematosus (SLE)**. The primary objective is to compare the efficacy of anifrolumab with placebo on overall disease activity in patients with SLE. The trial is expected to last until January 2026, with participant recruitment having commenced in June 2021. The study involves a series of visits, starting with a screening visit to confirm eligibility based on specific inclusion criteria, such as a diagnosis of SLE according to the ACR 1997 revised criteria and a total SLEDAI-2K score of at least 6 points.

Participants will be randomly assigned to receive either anifrolumab or placebo, administered via an accessorized prefilled syringe for subcutaneous use. The trial includes multiple follow-up visits to monitor the participants' response to the treatment and to assess any adverse effects. The primary endpoint is the BICLA composite binary response, with secondary endpoints including the proportion of BICLA responders at Week 52 and the time to flare through Week 52. The expected duration of participant involvement is up to 104 weeks, with conditions for early termination including significant adverse events or withdrawal of consent. The end-of-study visit will conclude the trial, where final assessments will be conducted to evaluate the long-term effects of the treatment.

The clinical trial involves the administration of **Anifrolumab**, a **solution for injection** developed by AstraZeneca AB. Anifrolumab is a protein-based therapeutic agent classified under the category "Protein - Other." The pharmaceutical form of Anifrolumab is a solution intended for subcutaneous use. The medication is delivered using an accessorized prefilled syringe (APFS) specifically designed for subcutaneous administration. The dosing regimen for Anifrolumab is structured to ensure optimal therapeutic outcomes, with a maximum treatment period of 104 weeks. The trial does not specify a maximum daily or total dose amount, indicating that dosing is likely tailored to individual patient needs within the study parameters.

In this study, Anifrolumab is compared against a **placebo** to evaluate its efficacy and safety in adult patients diagnosed with **Systemic Lupus Erythematosus (SLE)**. The placebo serves as a control to assess the overall disease activity and the therapeutic impact of Anifrolumab. The trial is designed as a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study, ensuring rigorous evaluation of the investigational product. Participant compliance with the dosing schedule is monitored throughout the study to maintain the integrity of the trial data and ensure accurate assessment of the treatment's efficacy and safety profile.

The efficacy of **anifrolumab** in the treatment of Systemic Lupus Erythematosus (SLE) will be assessed using a primary endpoint and several secondary endpoints. The primary endpoint is the BICLA (British Isles Lupus Assessment Group-based Composite Lupus Assessment), a composite binary response that requires meeting all specified criteria. Secondary endpoints include the proportion of patients who are BICLA responders at Week 52 and have maintained low or reduced oral steroid use through Week 52, the time from the first dose of the study intervention to the first sustained BICLA response through Week 52, and the time to flare through Week 52, where a flare is defined as one or more new BILAG-2004 A or two or more new BILAG-2004 B items compared to the previous visit.